Evidence map›Paper›PMID 41947782›Full record

Observational studyInternational journal of chronic obstructive pulmonary disease2026

Prognostic Value of Impaired Spirometry in Patients with Myocardial Infarction: A Longitudinal Study of Two European Cohorts.

Josefin Sundh, William A E Parker, Jonas Oldgren, Pontus Andell, Christian Reitan, Tomas Jernberg, Robin Hofmann, Moman A Mohammad, David Erlinge, Axel Åkerblom and 13 more

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in International journal of chronic obstructive pulmonary disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Josefin Sundh *Department of Respiratory Medicine, Örebro University Hospital; Faculty of Medicine and Health, School of Medical Sciences, Örebro University, Örebro, Sweden.ORCID 0000-0003-1926-8464
William A E Parker *Cardiovascular Research Unit, Division of Clinical Medicine, University of Sheffield, Sheffield, UK.ORCID 0000-0002-7822-8852
Jonas OldgrenDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Pontus AndellDepartment of Physiology and Pharmacology, Karolinska Institutet, and ME Cardiology, Karolinska University Hospital, Stockholm, Sweden.
Christian ReitanDepartment of Clinical Science, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.
Tomas JernbergDepartment of Clinical Science, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.
Robin HofmannDepartment of Clinical Science and Education, Division of Cardiology, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-8907-895X
Moman A MohammadDepartment of Cardiology, Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden.ORCID 0000-0003-4242-9801
David ErlingeDepartment of Cardiology, Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden.
Axel ÅkerblomDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Sofia Sederholm LawessonClinical Department of Cardiology, Region Östergötland and Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
Kyriakos V KonstantinidisGlobal Project, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Johan LindbäckUppsala Clinical Research Centre, Uppsala University, Uppsala, Sweden.ORCID 0000-0002-6473-8798
Christer JansonDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.ORCID 0000-0001-5093-6980
Anna BjörkenheimDepartment of Cardiology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Nadir ElaminCardiovascular Research Unit, Division of Clinical Medicine, University of Sheffield, Sheffield, UK.
Hannah McMellonCardiovascular Research Unit, Division of Clinical Medicine, University of Sheffield, Sheffield, UK.
Bethany MoyleCardiovascular Research Unit, Division of Clinical Medicine, University of Sheffield, Sheffield, UK.
Mehul PatelClinical Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.ORCID 0000-0003-0435-858X
Jad El KhouryGlobal Medical Affairs, Global Medical Affairs, Cardiovascular, Renal & Metabolic Disease, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.ORCID 0009-0002-0300-7198
Raulin SurujballyGlobal Clinical Operations, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Stefan James *Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Robert F Storey *Cardiovascular Research Unit, Division of Clinical Medicine, University of Sheffield, Sheffield, UK.ORCID 0000-0002-6677-6229

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The study aimed to investigate the associations between impaired spirometry such as obstructive pattern and preserved ratio impaired spirometry (PRISm) and occurrent cardiovascular events and deaths in patients with acute myocardial infarction. Patients and Methods: Cohort study of 517 patients with age ≥40 years and ≥10 pack-years of smoking, hospitalized for myocardial infarction at eight sites in Sweden and the United Kingdom. The Vitalograph Results: Obstructive pattern was found in 95 (18%), PRISm in 192 (37%) and normal spirometry in 230 (45%) patients. A cardiovascular event occurred in 21 (4%) and MACE in 28 (5%). Compared with normal spirometry, PRISm was independently associated with both new cardiovascular events (HR (95% CI) 3.44 (1.07-11.0)) and MACE (4.94 (1.63 to 15.0)), and obstructive pattern with MACE (3.87 (1.08-13.8)). Further adjustment for cardiac or COPD treatment did not substantially change the results. Conclusion: About half of patients with acute myocardial infarction and a ≥10 pack-year smoking history have abnormal spirometry findings. Both obstructive pattern and PRISm are independently associated with increased risk for MACE within one year. We suggest that spirometry should be considered as a routine assessment in patients with smoking history and recent myocardial infarction.

Indexed as

LungMyocardial InfarctionPulmonary Disease, Chronic ObstructiveSpirometryAdultAgedFemaleForced Expiratory VolumeHumansIncidenceKaplan-Meier EstimateLongitudinal StudiesMaleMiddle AgedMultivariate AnalysisPredictive Value of Testsacute ischemic cardiovascular eventschronic obstructive pulmonary diseaseCOPDMACEmajor adverse cardiovascular eventsobstructive patternpreserved ratio impaired spirometryPRISm

Identifiers

PMID41947782
PMCPMC13052249

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.